Collecting blood from people with HIV to study immune control
Collects white blood cells and plasma from adults with HIV who control the virus long-term.
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 9 Aug 2001
- Type of study
- Observational, 3 groups
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who can safely have blood collected. It includes people with HIV, including long-term non-progressors, and HIV-negative family members of such people.
- Age
- 18 Years to 100 Years
- Sex
- All sexes
- Disease stage
- HIV-positive people who are long-term non-progressors (LTNP) or progressors. HIV-negative family members of HIV-positive people who control the virus can also join.
- Biomarker or test result
- HIV-seropositive status, or HIV-negative family member of someone whose immune system controls HIV. HLA class I type does not matter.
Main reasons for not taking part
- Pregnant
- Heart or circulation instability, severe anemia, severe clotting disorder
- Veins not good enough for apheresis or the research blood draw
- Any condition the investigator thinks makes joining unsafe
The registry criteria, word for word
Show all 7 criteriaShow less
Who cannot take part
- Cardiovascular instability, severe anemia, inadequate venous access, severe coagulation disorder, or any other condition that the Principal Investigator or Apheresis Unit staff considers a contraindication to the apheresis procedure or research blood draw
- Any condition that, in the opinion of the investigator, contraindicates participation in this study
- Pregnant
Other criteria
- INCLUSION CRITERIA:; Adult (18 years-old or older); Eligibility to undergo apheresis procedures; or, for participants who are unable to undergo apheresis, willingness to undergo blood draw for research purposes that remain within safety guidelines established by NIH policy; Willingness to give informed consent for the storage of blood or tissue samples and HLA testing; AND at least one of the following:
- An HIV-seropositive participant categorized as an LTNP as defined by clinical and laboratory criteria, regardless of HLA class I type
- HIV-seropositive progressors
- Persons who are seronegative for HIV but are family members of seropositive participants exhibiting immunologic control of HIV
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Daniel C Rogan, M.D.Taking people
About the trial
What the trial wants to find out
This study will collect white blood cells and plasma for research on how the immune system controls HIV infection. The immune system of a very small group of people with HIV, called non-progressors, has been able to control HIV for long periods without antiretroviral therapy. Some immune system-related genes important for this control have been identified in these patients.
Read full original descriptionShow less
People living with HIV who are 18 years of age and older, documented or suspected long-term nonprogressors in generally good health may be eligible to screen for the study.
Participants will undergo apheresis (a method for collecting larger quantities of certain blood components than can safely be collected through a simple blood draw) if venous access is adequate once yearly. Some may be asked to return every six months.
* Automated apheresis - Blood is drawn through a needle placed in an arm vein and spun in a machine, separating the blood components. The white cells are extracted and the red cells, with or without plasma (liquid part of the blood), are re-infused into the donor through a needle in the other arm. An anticoagulant (medication to prevent blood from clotting) is usually added to the blood while in the machine to prevent it from clotting during processing. * Blood draw - a needle placed in an arm vein for large volume (approx 75ml) blood draw if veins considered inadequate for apheresis procedure.
Some of the blood collected through apheresis may be stored for future studies of HIV disease and immune function and for HLA testing, a genetic test of markers of the immune system.
The 3 groups in the trial
- Family members
Family members of individuals with innate control over HIV
- HIV infection with one of the following HLA types: B*27+, B*35+,B*44+, B*57+, B*58+, and/or A*02.
People living with HIV with specific HLA-types.
- Long term nonprogressors
Individuals with innate control over HIV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity
- Plain-language title
- Collecting blood from people with HIV to study immune controlGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT00029445, who can take part
- Record updated
- 27 October 2026